Phibro Animal Health (NASDAQ:PAHC) Releases FY 2025 Earnings Guidance

Phibro Animal Health (NASDAQ:PAHC) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 1.340-1.480 for the period, compared to the consensus estimate of 1.550. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.2 billion.

Phibro Animal Health Price Performance

NASDAQ PAHC traded up $0.35 during trading on Friday, reaching $23.85. The company’s stock had a trading volume of 203,227 shares, compared to its average volume of 158,175. The stock has a market capitalization of $966.00 million, a PE ratio of 55.47, a P/E/G ratio of 0.57 and a beta of 0.51. The company has a debt-to-equity ratio of 1.79, a current ratio of 2.94 and a quick ratio of 1.64. The firm has a fifty day moving average of $22.37 and a 200 day moving average of $19.38. Phibro Animal Health has a one year low of $9.40 and a one year high of $25.11.

Phibro Animal Health (NASDAQ:PAHC) last announced its earnings results on Wednesday, August 28th. The company reported $0.41 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.07. Phibro Animal Health had a net margin of 1.67% and a return on equity of 21.44%. The business had revenue of $273.16 million for the quarter, compared to the consensus estimate of $262.44 million. Analysts expect that Phibro Animal Health will post 1.57 EPS for the current fiscal year.

Phibro Animal Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 18th. Investors of record on Wednesday, November 27th will be given a $0.12 dividend. The ex-dividend date of this dividend is Wednesday, November 27th. This represents a $0.48 annualized dividend and a yield of 2.01%. Phibro Animal Health’s dividend payout ratio (DPR) is presently 111.63%.

Wall Street Analyst Weigh In

PAHC has been the subject of several research analyst reports. Bank of America lifted their price target on Phibro Animal Health from $13.00 to $15.00 and gave the stock an “underperform” rating in a research note on Friday, August 30th. JPMorgan Chase & Co. assumed coverage on Phibro Animal Health in a research report on Tuesday, September 10th. They issued a “neutral” rating and a $22.00 target price for the company. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $15.00.

Insider Activity

In related news, Director E Thomas Corcoran bought 5,000 shares of the stock in a transaction dated Wednesday, September 4th. The stock was bought at an average price of $20.02 per share, with a total value of $100,100.00. Following the purchase, the director now owns 25,000 shares in the company, valued at approximately $500,500. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 50.07% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.